As filed pursuant to Rule 424(b)(5)
Registration No. 333-255105
PROSPECTUS SUPPLEMENT
(To prospectus dated April 7, 2021)
Amyris, Inc.
20,000,000 Shares of Common Stock
Warrants to Purchase 15,000,000 Shares of Common Stock
We are offering 20,000,000 shares of our common stock, $0.0001 par value per share (our common stock), and warrants to purchase up to 15,000,000 shares of common stock (our warrants) in a registered direct offering directly to certain investors (the investors) pursuant to this prospectus supplement and the accompanying prospectus and securities purchase agreement with the investors. This prospectus supplement also relates to the offering of the shares of common stock issuable upon exercise of such warrants. The common stock and warrants will be sold in units, with each unit consisting of one share of common stock and one warrant to purchase 0.75 of a share of common stock. Each warrant will be immediately exercisable at a price of $1.80 per full share of common stock for a period of five years from the date such warrant first becomes exercisable. Each unit will be sold to investors at an offering price of $1.50. Warrants may only be exercised for whole numbers of shares of common stock. The shares of common stock and warrants are immediately separable and will be issued separately.
In a concurrent private placement, we are selling to our affiliate Foris Ventures, LLC (Foris) 13,333,334 shares of our common stock and warrants to purchase up to 10,000,000 shares of common stock. The common stock and warrants will be sold in units, with each unit consisting of one share of common stock and one warrant to purchase 0.75 of a share of common stock. Each warrant will be immediately exercisable at a price of $1.80 per full share of common stock for a period of five years from the date such warrant first becomes exercisable. Each unit will be sold to investors at an offering price of $1.50. Warrants may only be exercised for whole numbers of shares of common stock. The shares of common stock and warrants are immediately separable and will be issued separately. The shares of common stock and warrants being offered in the concurrent private placement are being offered pursuant to the exemptions provided in Section 4(a)(2) under the Securities Act of 1933, as amended, or the Securities Act, and Rule 506(b) promulgated thereunder, and they are not being offered pursuant to this prospectus supplement and the accompanying prospectus. The concurrent private placement is expected to close concurrently with this offering and on substantially the same terms and conditions as this offering.
Our common stock is listed on The Nasdaq Global Select Market under the symbol AMRS. On December 28, 2022, the closing price of our common stock was $1.67 per share. We do not intend to list the warrants on The Nasdaq Global Market, any other national securities exchange or any other nationally recognized trading system. Without an active trading market, the liquidity of the warrants will be limited.
Investing in our securities involves risks. See Risk Factors on page S-7.
You should carefully read this prospectus supplement, the documents incorporated herein, and, if applicable, any prospectus supplement subsequently filed with respect to the accompanying prospectus, before making any investment decision.
We engaged H.C. Wainwright & Co., LLC as our exclusive placement agent to use its reasonable best efforts to solicit offers to purchase shares of our securities in connection with this offering. The placement agent has no obligation to purchase any of the shares of our securities from us or to arrange for the purchase or sale of any specific number or dollar amount of the securities. We have agreed to pay the placement agent the placement agent fees set forth in the table below and to provide certain other compensation to the placement agent. See Plan of Distribution beginning on page S-19 of this prospectus supplement for more information regarding these arrangements.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
Per Unit |
Total | |||||||
Offering price |
$ | 1.50 | $ | 30,000,000 | ||||
Placement Agent fees(1) |
$ | 0.105 | $ | 2,100,000 | ||||
Proceeds to Amyris, Inc., before expenses |
$ | 1.395 | $ | 27,900,000 | ||||
|
|
|
|
(1) | We have agreed to pay the placement agent for certain of its expenses. See Plan of Distribution on page S-19 of this prospectus supplement for a description of the compensation payable to the placement agent. |
We expect to deliver the shares of common stock and warrants against payment on or about December 30, 2022, subject to satisfaction of customary closing conditions.
H.C. Wainwright & Co.
The date of this prospectus supplement is December 29, 2022
PROSPECTUS SUPPLEMENT |
| |||
S-Page | ||||
S-1 | ||||
S-3 | ||||
S-7 | ||||
S-11 | ||||
S-12 | ||||
S-13 | ||||
S-15 | ||||
S-17 | ||||
S-19 | ||||
S-21 | ||||
S-21 | ||||
S-21 | ||||
S-22 | ||||
PROSPECTUS
|
| |||
PAGE | ||||
1 | ||||
3 | ||||
4 | ||||
5 | ||||
6 | ||||
10 | ||||
11 | ||||
19 | ||||
20 | ||||
22 | ||||
22 | ||||
22 | ||||
23 |
i
ABOUT THIS PROSPECTUS SUPPLEMENT
This document is in two parts. The first part is this prospectus supplement, which describes the specific terms of this offering of shares of common stock, warrants and units. The second part is the accompanying prospectus, which provides more general information, some of which may not apply to this offering. The information included or incorporated by reference in this prospectus supplement also adds to, updates and changes information contained or incorporated by reference in the accompanying prospectus. If information included or incorporated by reference in this prospectus supplement is inconsistent with the accompanying prospectus or the information incorporated by reference therein, then this prospectus supplement or the information incorporated by reference in this prospectus supplement will apply and will supersede the information in the accompanying prospectus and the documents incorporated by reference therein.
This prospectus supplement is part of an automatic registration statement that we filed with the Securities and Exchange Commission (the Commission) as a well-known seasoned issuer as defined in Rule 405 of the Securities Act of 1933, as amended, or the Securities Act, using a shelf registration process. Under the shelf registration process, we may from time to time offer and sell any combination of the securities described in the accompanying prospectus.
Neither we nor the Placement Agent has authorized any other person to provide you with information different from that contained in this prospectus supplement and the accompanying prospectus or incorporated by reference in this prospectus supplement and the accompanying prospectus. Neither we nor the placement agent take any responsibility for, and provide no assurance as to the reliability of, any other information that others may give you. We are not making an offer to sell or soliciting an offer to buy these securities under any circumstance in any jurisdiction where the offer or solicitation is not permitted. You should assume that the information contained in this prospectus supplement, the accompanying prospectus and any free writing prospectus prepared by us or on our behalf is accurate only as of the date of the respective document in which the information appears, and that any information in documents that we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus supplement or any sale of a security. Our business, financial condition, results of operations and prospects may have changed since those dates.
It is important for you to read and consider all of the information contained in this prospectus supplement and the accompanying prospectus in making your investment decision. We include cross-references in this prospectus supplement and the accompanying prospectus to captions in these materials where you can find additional related discussions. The table of contents in this prospectus supplement provides the pages on which these captions are located. You should read both this prospectus supplement and the accompanying prospectus, together with the additional information described in the sections entitled Where You Can Find More Information and Incorporation of Information by Reference of this prospectus supplement, before investing in our common stock.
We are offering to sell, and seeking offers to buy, the units only in jurisdictions where offers and sales are permitted. The distribution of this prospectus supplement and the accompanying prospectus and the offering of the units in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus supplement and the accompanying prospectus must inform themselves about, and observe any restrictions relating to, the offering of the units and the distribution of this prospectus supplement and the accompanying prospectus outside the United States. This prospectus supplement and the accompanying prospectus do not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus supplement and the accompanying prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation.
S-1
The information in this prospectus supplement is accurate only as of the date on the front cover of this prospectus supplement and the information in any free writing prospectus that we may provide you in connection with this offering is accurate only as of the date of that free writing prospectus. Our business, financial condition, results of operations and prospects may have changed since those dates. No person is authorized in connection with this prospectus supplement or the accompanying prospectus to give any information or to make any representations about us, the securities offered hereby or any matter discussed in this prospectus supplement or the accompanying prospectus, other than the information and representations contained in this prospectus supplement or the accompanying prospectus. If any other information or representation is given or made, such information or representation may not be relied upon as having been authorized by us.
For investors outside the United States: We have not taken any action that would permit this offering or possession or distribution of this prospectus supplement or the accompanying prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus supplement or the accompanying prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities covered hereby and the distribution of this prospectus supplement or the accompanying prospectus outside the United States.
All references in this prospectus supplement and the accompanying prospectus to our consolidated financial statements include the related notes thereto.
Unless the context otherwise requires, AMRS, Amyris, the Company, we, us, our and similar names refer to Amyris, Inc.
S-2
This summary highlights information contained in other parts or incorporated by reference in this prospectus supplement and the accompanying prospectus from our Annual Report on Form 10-K for the year ended December 31, 2021, and our other filings with the Securities and Exchange Commission, or the Commission, listed below under the heading Incorporation by Reference. This summary does not contain all the information that you should consider before investing in our securities. You should carefully read this entire prospectus supplement, accompanying prospectus and the documents incorporated by reference in this prospectus supplement and the accompanying prospectus carefully, including Risk Factors and the financial statements and related notes and other information incorporated by reference, before making an investment decision.
About Amyris, Inc.
We are a biotechnology company at the forefront of delivering sustainable science-based solutions that are better for people and the planet. To accelerate the worlds transition to sustainable consumption, we create,
manufacture and commercialize consumer products and ingredients that reach more than 300 million consumers. Currently, the largest source of revenue is the marketing and selling of Clean Beauty, Personal Care and
Health & Wellness consumer products through our direct-to-consumer ecommerce platforms and a growing network of retail partners. We also sell sustainable ingredients to sector leaders that serve Flavor & Fragrance (F&F), Nutrition, Food & Beverage, and Clean Beauty & Personal Care end markets.
Our ingredients and consumer products are powered by our Lab-to-MarketTM technology platform. This technology platform enables the portfolio connection between our proprietary science and formulation expertise, manufacturing capability at industrial scale, and expertise in commercializing high performance, sustainable products that make a difference in peoples lives. We believe that our technology platform offers advantages to traditional methods of sourcing similar ingredients (such as petrochemistry and extraction from organisms). Our technology platform allows for renewable and ethical sourcing of raw materials, less resource-intensive production, minimal impact on sensitive ecosystems, enhanced purity and safety profiles, less vulnerability to climate disruption, and improved supply chain resilience. We combine molecular biology and genetic engineering to generate more sustainable materials that are otherwise derived from scarce or endangered resources in nature. We leverage state-of-the-art machine learning, robotics and artificial intelligence to rapidly bring new innovation to market.
Concurrent Private Placement of Common Stock and Warrants
In a concurrent private placement, we intend to sell an aggregate of 13,333,334 shares of common stock and warrants to purchase up to 10,000,000 shares of common stock, directly to Foris in a private placement at a price of $1.50 per unit, for aggregate gross proceeds to us of approximately $20.0 million. Foris is a beneficial owner of greater than five percent of our outstanding common stock and affiliated with director John Doerr and director Ryan Pandchadsaram. The shares of common stock and warrants being offered in the concurrent private placement are being offered pursuant to the exemptions provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder, and they are not being offered pursuant to this prospectus supplement and the accompanying prospectus.
Corporate Information
We were originally incorporated in California in 2003 under the name Amyris Biotechnologies, Inc. and then reincorporated in Delaware in 2010 and changed our name to Amyris, Inc. Our principal executive offices are located at 5885 Hollis Street, Suite 100, Emeryville, California 94608, and our telephone number is (510) 450-0761. Our common stock is listed on The Nasdaq Global Select Market under the symbol AMRS. Our
S-3
website address is www.amyris.com. The information contained in or accessible through our website or contained on other websites is not a part of, and not incorporated into, this prospectus supplement.
Amyris, the Amyris logo, and Lab-to-Market are trademarks or registered trademarks of Amyris, Inc. or its subsidiaries. This report also contains trademarks and trade names of other businesses that are the property of their respective holders. Solely for convenience, the trademarks and tradenames referred to in this prospectus supplement appear without the ® and symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the applicable licensor to these trademarks and tradenames.
S-4
THE OFFERING
Common Stock Offered by Us |
20,000,000 shares. |
Warrants Offered by Us |
Warrants to purchase up to an additional 15,000,000 shares of common stock. This prospectus supplement also covers the shares of common stock issuable upon exercise of the warrants. There is currently no market for the warrants and none is expected to develop after this offering. |
Purchase Price |
$1.50 per unit |
Terms of Warrants |
An exercise price of $1.80 per share of common stock, exercisable immediately following the date of issuance and expiring 5 years from the date such warrant first become exercisable. See Description of SecuritiesWarrants |
Concurrent Private Placement |
In a concurrent private placement, we are selling to Foris, an affiliate of ours, 13,333,334 shares of our common stock and warrants to purchase up to 10,000,000 shares of common stock. The common stock and warrants will be sold in units, with each unit consisting of one share of common stock and one warrant to purchase 0.75 of a share of common stock. Each warrant will be immediately exercisable at a price of $1.80 per full share of common stock for a period of five years from the date such warrant first becomes exercisable. Each unit will be sold to investors at an offering price of $1.50. The concurrent private placement is expected to close concurrently with this offering and on substantially the same terms and conditions as this offering. |
Common Stock Outstanding after this offering and the concurrent private placement |
363,491,815 shares. |
Use of Proceeds |
We estimate that our net proceeds from this offering and the concurrent private placement will be approximately $47.7 million, after deducting estimated offering expenses payable by us. |
We intend to use the net proceeds we receive from this offering and the concurrent private placement, together with our existing cash, cash equivalents and investments, for general corporate purposes. See Use of Proceeds for additional information. |
Risk Factors |
See Risk factors beginning on page S-5 of this prospectus supplement and other information included and incorporated by reference in this prospectus supplement and the accompanying prospectus for a discussion of factors that you should carefully consider before deciding to invest in this offering. |
Nasdaq Symbol |
AMRS. |
S-5
The number of shares of our common stock to be outstanding immediately after this offering is based on 324,885,832 shares of our common stock outstanding as of September 30, 2022 and excludes:
| 4,621,782 shares of common stock issuable upon exercise of options outstanding as of September 30, 2022, with a weighted-average exercise price of $7.00; |
| 17,148,515 shares of common stock issuable upon vesting of restricted stock units, or RSUs, outstanding as of September 30, 2022; |
| 96,151 shares of common stock issuable upon exercise of options granted after September 30, 2022, with a weighted-average exercise price of $2.333; |
| 959,372 shares of common stock issuable upon vesting of RSUs granted after September 30, 2022; |
| 3,692,646 shares of common stock issuable upon the exercise of outstanding warrants and rights as of September 30, 2022, with a weighted-average exercise price of $3.51; |
| 106,798,571 shares of common stock reserved for issuance upon the exercise of conversion rights of holders of our outstanding convertible debt securities; |
| 20,694,213 shares of common stock reserved for future issuance as of September 30, 2022 under our 2020 Equity Incentive Plan (the 2020 EIP) and our 2010 Equity Incentive Plan (the 2010 EIP, and together with the 2020 EIP, the EIP Plans); and |
| 3,801,169 shares of common stock reserved for future issuance as of September 30, 2022 under our 2010 Employee Stock Purchase Plan (the 2010 ESPP). |
Unless otherwise indicated, all information in this prospectus supplement assumes or gives effect to:
| no exercise of the outstanding options or settlement of the outstanding RSUs referred to above; |
| no exercise of the outstanding warrants referred to above; |
| no conversion of the outstanding convertible debt securities referred to above; and |
| no exercise by the underwriters of their option to purchase additional shares. |
| the issuance of shares and warrants in the concurrent private placement described under Private Placement Transaction, but not the exercise of such warrants. |
S-6
Investing in our securities involves a high degree of risk. You should carefully read and consider the specific factors discussed below, together with all of the other information contained or incorporated by reference in this prospectus supplement or appearing or incorporated by reference in the prospectus. You should also consider the risks, uncertainties and assumptions discussed under the heading Risk Factors in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2021 and in Part II, Item 1A of any subsequently filed Quarterly Reports on Form 10-Q filed with the Commission, which are incorporated herein by reference. Additional risks and uncertainties beyond those set forth in our reports filed with the Commission and not presently known to us or that we currently deem immaterial may also affect our operations. Any risks and uncertainties, whether set forth in our reports filed with the Commission or otherwise, could cause our business, financial condition, results of operations and future prospects to be materially and adversely harmed. The trading price of our securities could decline due to any of these risks and uncertainties, and, as a result, you may lose all or part of your investment.
Risks Related to this Offering
We have broad discretion in the use of our existing cash, cash equivalents and investments and the net proceeds from this offering and concurrent private placement and may not use them effectively.
Our management will have broad discretion in the application of our existing cash, cash equivalents and investments and the net proceeds from this offering and the concurrent private placement, including for any of the purposes described in the section titled Use of Proceeds, and you will not have the opportunity as part of your investment decision to assess whether such proceeds are being used appropriately. Because of the number and variability of factors that will determine our use of our existing cash and cash equivalents and the net proceeds from this offering and the concurrent private placement, their ultimate use may vary substantially from their currently intended use. Our management might not apply our existing cash and cash equivalents and the net proceeds from this offering in ways that ultimately increase the value of your investment. The failure by our management to apply these funds effectively could harm our business. Pending their use, we may invest the net proceeds from this offering in short-term, investment-grade, interest-bearing securities. These investments may not yield a favorable return to our stockholders. If we do not invest or apply the net proceeds from this offering in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause our stock price to decline.
Our stock price has been, and may continue to be, volatile.
The market price of our common stock has been, and may continue to be, subject to material volatility. Such fluctuations could be in response to, among other things, the factors described in this Risk Factors section, or other factors, some of which are beyond our control, such as:
| the ongoing impacts of the COVID-19 pandemic and resulting impact on stock market performance; |
| fluctuations in our financial results or outlook, or those of companies perceived to be similar to us; |
| changes in estimates of our financial results or recommendations by securities analysts; |
| changes in the prices of commodities associated with our business or changes in the prices of commodities that some of our products may replace, such as oil and other petroleum sourced products; |
| changes in our capital structure, such as future issuances of securities or the incurrence of debt; |
| announcements by us or our competitors of significant contracts, acquisitions or strategic partnerships; |
| regulatory developments in the United States, Brazil, and/or other foreign countries; |
| litigation involving us or our general industry; |
S-7
| additions or departures of key personnel; |
| investors general perceptions of us; and |
| changes in general economic, industry and market conditions including global inflation and policy measures undertaken to address inflation. |
Furthermore, stock markets have experienced price and volume fluctuations that have affected, and continue to affect, the market prices of equity securities of many companies. These fluctuations often have been unrelated or disproportionate to the operating performance of those companies. These broad market fluctuations, as well as general economic, political and market conditions, such as recessions, interest rate changes and international currency fluctuations, may negatively affect the market price of our common stock.
Additionally, the global economy and financial markets may be adversely affected by geopolitical events, including the current or anticipated impact of military conflict and related sanctions imposed on Russia by the United States and other countries due to Russias recent invasion of Ukraine.
In the past, many companies that have experienced volatility and sustained declines in the market price of their stock have become subject to securities class action and derivative action litigation. We have been involved in such lawsuits in the past and are currently defending such lawsuits, and we may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our managements attention from other business concerns, which could materially harm our business. Any insurance we maintain may not provide adequate coverage against potential losses from such securities litigation, and if claims or losses exceed our liability insurance coverage, our business would be adversely impacted. In addition, insurance coverage may become more expensive, which would harm our financial condition and results of operations.
The concentration of our capital stock ownership and certain rights we have granted to insiders will limit the ability of other stockholders to influence corporate matters and presents risks related to our future securities offerings, which could substantially impact our business.
As of September 30, 2022, over 30% of our capital stock was beneficially owned by three significant stockholders, including Foris , DSM International B.V., and Vivo Capital LLC (Vivo). Furthermore, Foris and other insider stockholders hold some or a combination of convertible preferred stock, warrants and purchase rights, pursuant to which they may acquire additional shares of our common stock and thereby increase their ownership interest in the Company. Additionally, Foris is indirectly owned by John Doerr and Ryan Pandchadsaram, two of our current directors, and each of DSM and Vivo have one director on our Board of Directors pursuant to designation rights under their respective agreements with the Company. This significant concentration of share ownership may adversely affect the trading price of our common stock because investors often perceive disadvantages in owning stock in companies with stockholders with significant interests. Also, these stockholders, acting together, may be able to control or materially influence our management and affairs and matters requiring stockholder approval, including the election of directors and the approval of significant corporate transactions such as mergers, consolidations or the sale of all or substantially all of our assets, and may not act in the best interests of our other stockholders. Consequently, this concentration of ownership may have the effect of delaying or preventing a change of control or a change in our management or Board of Directors, or discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of the Company, even if such actions would benefit our other stockholders.
While we have a related party transactions policy that requires certain approvals of any transaction between the Company and a significant stockholder or its affiliates, there can be no assurance that our significant stockholders will act in the best interests of our other stockholders, which could harm our results of operations and cause our stock price to decline.
S-8
If you purchase securities sold in this offering, you will incur immediate and substantial dilution.
If you purchase shares of our common stock in this offering, you will experience substantial and immediate dilution in the as adjusted net tangible book value per share after giving effect to this offering, based on the public offering price of $1.50 per unit, because the price that you pay will be substantially greater than the as adjusted net tangible book value per share of the common stock that you acquire. This dilution is due in large part to the fact that certain of our earlier investors paid substantially less than the offering price when they purchased shares of our capital stock. You will experience additional dilution upon exercise of the outstanding stock options and other equity awards that may be granted under our equity incentive plans, and when we otherwise issue additional shares of our common stock. For more information, see Dilution .
Future sales and issuances of our common stock, convertible securities, warrants or rights to purchase common stock could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to decline.
From time to time, we have sold a substantial number of warrants and rights to acquire our common stock as well as convertible securities, which, if exercised, purchased, or converted, result in dilution to our stockholders. For example, in November 2021, we sold $690.0 million of 2026 Convertible Senior Notes. In the future, we may sell additional warrants, rights, convertible or exchangeable securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time, to finance our business operations and investments. To the extent we raise capital by issuing equity securities, our stockholders may experience substantial dilution.
If our existing stockholders, particularly our largest stockholders, our directors, their affiliates, or our executive officers, sell a substantial number of shares of our common stock in the public market, the market price of our common stock could decrease materially. The perception in the public market that these stockholders might sell our common stock could also depress the market price of our common stock and could impair our future ability to obtain capital, especially through an offering of equity securities.
We have in place, or have agreed to file, registration statements for the resale of certain shares of our common stock held by, or issuable to, certain of our largest stockholders. All of our common stock sold pursuant to an offering covered by such registration statements will be freely transferable. In addition, shares of our common stock issued or issuable under our equity incentive plans to employees and directors have been registered on Form S-8 registration statements and may be freely sold in the public market upon issuance, except for shares held by affiliates who have certain restrictions on their ability to sell.
We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.
We do not anticipate declaring any cash dividends to holders of our common stock in the foreseeable future. In addition, certain of our equipment leases and credit facilities currently restrict our ability to pay dividends. Consequently, investors may need to rely on sales of their shares of our common stock after price appreciation, which may never occur, as the only way to realize any future gains on their investment. Investors seeking cash dividends should not purchase our common stock.
The warrants issued in this offering may not have any value.
The warrants will be exercisable on the date of issuance and will expire on the five-year anniversary of the date of issuance at an exercise price of $1.80 per share of common stock. In the event our common stock price does not exceed the exercise price of the warrants during the period when such warrants are exercisable, such warrants may not have any value.
S-9
There is no public market for the warrants being offered in this offering.
There is no public trading market for the warrants being offered in this offering, and we do not expect a market to develop. In addition, we do not intend to apply to list the warrants on any securities exchange or nationally recognized trading system, including the Nasdaq Global Market. Without an active market, the liquidity of the warrants will be limited.
Holders of warrants purchased in this offering will have no rights as common stockholders until such holders exercise their warrants and acquire our common stock.
Until holders of warrants acquire shares of our common stock upon exercise of the warrants, as applicable, holders of warrants will have no rights with respect to the shares of our common stock underlying such warrants, as applicable. Upon exercise of the warrants, the holders will be entitled to exercise the rights of a common stockholder only as to matters for which the record date occurs after the exercise date.
S-10
This prospectus supplement, the accompanying prospectus and the other documents we have filed with the Commission that are incorporated herein by reference contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties, including those discussed under
the heading Risk Factors below, include our liquidity and ability to fund operating and capital expenses, potential delays or failures in development, production and commercialization of products, and our reliance on third parties.
All statements other than statements of historical fact are statements that could be deemed to be forward-looking statements, including any projections of financing needs, revenue, expenses, earnings or losses from operations, or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning product research, development and commercialization plans and timelines; any statements regarding expected production capacities, volumes and costs; any statements regarding anticipated benefits of our products and expectations for commercial relationships; any statements regarding the impact of the COVID-19 pandemic and related health measures on our business, financial condition and liquidity; any other statements of expectation or belief; and any statements of assumptions underlying any of the foregoing. The words believe, anticipate, expect, estimate, intend, plan, project, will be, will continue, will result, seek, could, may, might, or any variations of such words or other words with similar meanings generally identify forward-looking statements.
Given these uncertainties, you should not place undue reliance on these forward-looking statements. You should read this prospectus supplement, the accompanying prospectus and the documents that we incorporate by reference in this prospectus supplement with the understanding that our actual future results may be materially different from what we expect.
The forward-looking statements in this prospectus supplement, the accompanying prospectus or other document we have filed with the Commission and incorporated herein represent our views as of the date thereof. We anticipate that subsequent events and developments will cause our views to change. All subsequent written or oral forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. However, while we may elect to update these forward-looking statements at some point in the future or to conform these statements to actual results or revised expectations, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this prospectus supplement, the accompanying prospectus or other document.
S-11
We estimate that the net proceeds from this offering and the concurrent private placement will be approximately $47.7 million after deducting estimated offering expenses payable by us.
We intend to use the net proceeds we receive from this offering and the concurrent private placement, together with our existing cash, cash equivalents and investments, for general corporate purposes, which may include working capital, capital expenditures, research and development expenditures, commercial expenditures, repayment of indebtedness, acquisitions of new technologies or businesses, and investments. The amounts that we actually spend for the purposes described above may vary significantly and will depend, in part, on the timing and amount of our future revenues, our future expenses and any potential acquisitions that we may propose.
S-12
If you invest in our common stock, your ownership interest will be diluted to the extent of the difference between the public offering price per share of our common stock and the as adjusted net tangible book value per share of our common stock immediately after this offering.
As of September 30, 2022, our historical net tangible book value was approximately $(661.0) million, or $(2.04) per share of our common stock, based upon 324,885,832 shares of our common stock outstanding as of September 30, 2022. Net tangible book value per share represents the amount of our tangible assets less our liabilities divided by the total number of shares of our common stock outstanding.
After giving effect to the sale by us of 20,000,000 shares of common stock in this offering (excluding shares of common stock issuable upon exercise of the warrants being offered in this offering) at an offering price of $1.50 per unit as well as the concurrent private placement and after deducting commissions and estimated aggregate offering expenses payable by us, our as adjusted net tangible book value as of September 30, 2022 would have been approximately $(613.3) million, or $(1.71) per share of our common stock. This represents an immediate increase in net tangible book value of $0.33 per share to our existing stockholders and an immediate dilution of $3.21 per share to investors in this offering.
The following table illustrates this per share dilution to new investors (assuming no exercise of any warrants offered hereby):
Offering price per share |
$ | 1.50 | ||||||
Net tangible book value per share as of September 30, 2022, before giving effect to this offering |
$ | 2.04 | ||||||
Increase in as adjusted net tangible book value per share after giving effect to this offering |
0.33 | |||||||
As adjusted net tangible book value per share, after giving effect to this offering |
$ | 1.71 | ||||||
|
|
|||||||
Dilution per share to investors purchasing our common stock in this offering |
$ | 3.21 | ||||||
|
|
The above discussion is based on 324,885,832 shares of our common stock outstanding as of September 30, 2022 and excludes:
| 4,621,782 shares of common stock issuable upon exercise of options outstanding as of September 30, 2022, with a weighted-average exercise price of $7.00; |
| 17,148,515 shares of common stock issuable upon vesting of RSUs, outstanding as of September 30, 2022; |
| 96,151 shares of common stock issuable upon exercise of options granted after September 30, 2022, with a weighted-average exercise price of $2.333; |
| 959,372 shares of common stock issuable upon vesting of RSUs granted after September 30, 2022; |
| 3,692,646 shares of common stock issuable upon the exercise of outstanding warrants and rights as of September 30, 2022, with a weighted-average exercise price of $3.51; |
| 106,798,571 shares of common stock reserved for issuance upon the exercise of conversion rights of holders of our outstanding convertible debt securities; |
| 20,694,213 shares of common stock reserved for future issuance as of September 30, 2022 under our EIP Plans; and |
| 3,801,169 shares of common stock reserved for future issuance as of September 30, 2022 under our 2010 ESPP. |
S-13
To the extent that outstanding options are exercised or other shares issued, investors purchasing our common stock in this offering will experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result
S-14
In this offering, we are offering units consisting of an aggregate of 20,000,000 shares of common stock and warrants to purchase up to 15,000,000 shares of our common stock. This prospectus supplement also relates to the shares of common stock issuable upon the exercise of warrants that are part of the units, and upon the exercise of the warrants we will issue to the placement agent in this offering.
Common Stock
The material terms and provisions of our common stock are described under the caption Description of Capital Stock starting of page 6 of the accompanying prospectus.
Warrants
The warrants to be issued in this offering as part of the units represent the right to purchase up to 0.75 shares of common stock at an initial exercise price of $1.80 per share. Each warrant may be exercised at any time and from time to time, exercisable on the date of issuance of this offering and having a term of 5 years from the date such warrants first become exercisable. We do not intend to apply for listing of the warrants on any securities exchange or other nationally recognized trading system and we do not expect such a market to develop. The description of the warrants in this prospectus supplement supplements the Description of Warrants in the accompanying prospectus.
Form
The warrants will be issued as individual warrant agreements to the investors. The form of warrant will be filed as an exhibit to our Current Report on Form 8-K that we expect to file with the SEC in connection with this offering.
Term
The warrants expire will expire on the five-year anniversary of the date of issuance.
Exercisability
The warrants are exercisable at any time after their original issuance. The warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice and by payment in full of the exercise price in immediately available funds for the number of shares of common stock purchased upon such exercise. If, and only if, a registration statement relating to the issuance of the shares underlying the warrants is not then effective or the prospectus therein is not available for use, a holder of warrants may exercise the warrants on a cashless basis. However, if an effective registration statement and the prospectus is available for the issuance of the shares underlying the warrants, a holder may only exercise the warrants through a cash exercise. No fractional shares of common stock will be issued in connection with the exercise of a warrant.
A holder (together with its affiliates) may not exercise any portion of the warrants to the extent that the holder (together with its affiliates) would beneficially own more than 4.99% (or, at the election of the holder prior to the date of issuance, 9.99%) of our outstanding common stock after exercise. The holder may increase or decrease this beneficial ownership limitation to any other percentage not in excess of 9.99%, upon notice to us, provided that, in the case of an increase of such beneficial ownership limitation, such notice shall not be effective until 61 days following notice to us.
Transferability
Subject to applicable laws, the warrants may be offered for sale, sold, transferred or assigned without our consent.
S-15
Exchange Listing
There is no established public trading market for the warrants and we do not expect a market to develop. We do not intend to list the warrants on The Nasdaq Global Market, any other national securities exchange or any other nationally recognized trading system. Without an active market, the liquidity of the warrants will be limited.
Fundamental Transactions
If, at any time while the warrants are outstanding, we directly or indirectly, in one or more related transactions, enter into a fundamental transaction, which includes any merger with or into another entity, sale of all or substantially all of our assets, tender offer or exchange offer, or reclassification of our common stock as further described in the warrants, then each holder shall become entitled to receive the same amount and kind of securities, cash or property as such holder would have been entitled to receive upon the occurrence of such fundamental transaction if the holder had been, immediately prior to such fundamental transaction, the holder of the number of shares of common stock then issuable upon exercise of such holders warrants. Any successor to us, surviving entity or the corporation purchasing or otherwise acquiring such assets shall assume the obligation to deliver to the holder such alternate consideration, and the other obligations, under the warrants. In addition, upon a fundamental transaction, the holder will have the right to require us to repurchase its warrant at its fair value using the Black Scholes option pricing formula in the warrants; provided, however, that, if the fundamental transaction is not within our control, including not approved by our board of directors, then the holder shall only be entitled to receive the same type or form of consideration (and in the same proportion), at the Black Scholes value of the unexercised portion of the warrant, that is being offered and paid to the holders of our common stock in connection with the fundamental transaction.
No Rights as a Stockholder
Except by virtue of such holders ownership of shares of our common stock, the holder of a warrant does not have the rights or privileges of a holder of our common stock, including any voting rights, until the holder exercises the warrant. In the event of certain distributions, including cash dividends, if any, to all holders of our common stock for no consideration, the holder of a warrant shall be entitled to participate in such distributions to the same extent as if a holder of shares of our common stock in which case such distribution shall be held in abeyance for the benefit of such holder until the warrant is exercised.
S-16
In a concurrent private placement, we are selling to Foris, an affiliate of ours, 13,333,334 shares of our common stock and warrants to purchase up to 10,000,000 shares of common stock. The common stock and warrants will be sold in units, with each unit consisting of one share of common stock and one warrant to purchase 0.75 of a share of common stock. Each warrant will be immediately exercisable at a price of $1.80 per full share of common stock for a period of five years from the date such warrant first becomes exercisable. Each unit will be sold to investors at an offering price of $1.50. The concurrent private placement is expected to close concurrently with this offering and on substantially the same terms and conditions as this offering.
The common stock, warrants and the shares of common stock issuable upon the exercise of such warrants are not being registered under the Securities Act, are not being offered pursuant to this prospectus supplement and the accompanying prospectus and are being offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act. Accordingly, investors may only sell shares of Common Stock issued upon exercise of the Purchase Warrants pursuant to an effective registration statement under the Securities Act covering the resale of those shares, an exemption under Rule 144 under the Securities Act or another applicable exemption under the Securities Act.
Common Stock
The material terms and provisions of our common stock are described under the caption Description of Capital Stock starting of page 6 of the accompanying prospectus.
Warrants
The warrants to be issued in this offering as part of the units represent the right to purchase up to 0.75 shares of common stock at an initial exercise price of $1.80 per share. Each warrant may be exercised at any time and from time to time, exercisable on the date of issuance of this offering and having a term of 5 years from the date such warrants first become exercisable. We do not intend to apply for listing of the warrants on any securities exchange or other nationally recognized trading system and we do not expect such a market to develop. The description of the warrants in this prospectus supplement supplements the Description of Warrants in the accompanying prospectus.
Form
The warrants will be issued as individual warrant agreements to the investors. The form of warrant will be filed as an exhibit to our Current Report on Form 8-K that we expect to file with the SEC in connection with this offering.
Term
The warrants expire will expire on the five-year anniversary of the date of issuance.
Exercisability
The warrants are exercisable at any time after their original issuance. The warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice and by payment in full of the exercise price in immediately available funds for the number of shares of common stock purchased upon such exercise. If, and only if, a registration statement relating to the issuance of the shares underlying the warrants is not then effective or the prospectus therein is not available for use, a holder of warrants may exercise the warrants on a cashless basis. However, if an effective registration statement and the prospectus is available for the issuance of the shares underlying the warrants, a holder may only exercise the warrants through a cash exercise. No fractional shares of common stock will be issued in connection with the exercise of a warrant.
S-17
Transferability
Subject to applicable laws, the warrants may be offered for sale, sold, transferred or assigned without our consent.
Exchange Listing
There is no established public trading market for the warrants and we do not expect a market to develop. We do not intend to list the warrants on The Nasdaq Global Market, any other national securities exchange or any other nationally recognized trading system. Without an active market, the liquidity of the warrants will be limited.
Fundamental Transactions
If, at any time while the warrants are outstanding, we directly or indirectly, in one or more related transactions, enter into a fundamental transaction, which includes any merger with or into another entity, sale of all or substantially all of our assets, tender offer or exchange offer, or reclassification of our common stock as further described in the warrants, then each holder shall become entitled to receive the same amount and kind of securities, cash or property as such holder would have been entitled to receive upon the occurrence of such fundamental transaction if the holder had been, immediately prior to such fundamental transaction, the holder of the number of shares of common stock then issuable upon exercise of such holders warrants. Any successor to us, surviving entity or the corporation purchasing or otherwise acquiring such assets shall assume the obligation to deliver to the holder such alternate consideration, and the other obligations, under the warrants. In addition, upon a fundamental transaction, the holder will have the right to require us to repurchase its warrant at its fair value using the Black Scholes option pricing formula in the warrants; provided, however, that, if the fundamental transaction is not within our control, including not approved by our board of directors, then the holder shall only be entitled to receive the same type or form of consideration (and in the same proportion), at the Black Scholes value of the unexercised portion of the warrant, that is being offered and paid to the holders of our common stock in connection with the fundamental transaction.
No Rights as a Stockholder
Except by virtue of such holders ownership of shares of our common stock, the holder of a warrant does not have the rights or privileges of a holder of our common stock, including any voting rights, until the holder exercises the warrant. In the event of certain distributions, including cash dividends, if any, to all holders of our common stock for no consideration, the holder of a warrant shall be entitled to participate in such distributions to the same extent as if a holder of shares of our common stock in which case such distribution shall be held in abeyance for the benefit of such holder until the warrant is exercised.
You should review a copy of the securities purchase agreement and a copy of the form of the warrant to be issued to the investors under the securities purchase agreement, which are executed or issued in connection with this offering and will be filed as exhibits to a Current Report on Form 8-K that we file with the SEC, for a complete description of the terms and conditions of the warrants and the related transaction agreements.
S-18
Pursuant to an engagement agreement, we have engaged H.C. Wainwright & Co., LLC, or the placement agent, to act as our exclusive placement agent in connection with this offering of our securities pursuant to this prospectus supplement. The placement agent has agreed to use reasonable best efforts to arrange for the sale of the securities pursuant to this prospectus supplement. The terms of this offering are subject to market conditions and negotiations between us, the placement agent and prospective investors. The engagement agreement does not give rise to any commitment by the placement agent to purchase any of our securities and the placement agent is not required to arrange the purchase or sale of any specific number or dollar amount of securities. The placement agent will have no authority to bind us by virtue of the engagement agreement and the placement agent does not guarantee that it will be able to raise new capital in any prospective offering. The placement agent may engage sub-agents or selected dealers to assist with the offering.
We have entered into a securities purchase agreement directly with institutional investors, who will purchase our securities in this offering, providing such investors with certain representations, warranties and covenants from us.
We will deliver the securities being issued to the investors upon receipt of investor funds for the purchase of the securities offered pursuant to this prospectus supplement. We expect to deliver the securities being offered pursuant to this prospectus on or about December 30, 2022.
The placement agent may distribute this prospectus supplement electronically.
Commissions and Expenses
We have agreed to pay the placement agent a total cash fee equal to 7.0% of the gross proceeds of this offering. The following table shows the per share of common stock and accompanying warrant and total placement agent fees payable to the placement agent by us in connection with this offering.
Per Unit |
Total | |||||||
Offering price |
$ | 1.50 | $ | 30,000,000 | ||||
Placement Agent fees(1) |
$ | 0.105 | $ | 2,100,000 | ||||
Proceeds to Amyris, Inc., before expenses |
$ | 1.395 | $ | 27,900,000 | ||||
|
|
|
|
We will also reimburse the placement agent for the placement agents legal fees and expenses in the amount of up to $50,000 and $15,950 for closing fees. We estimate the total offering expenses of this offering that will be payable by us, excluding placement agent fees, will be approximately $200,000.
Other Relationships
The placement agent and its respective affiliates have engaged in, and may in the future engage in, investment banking, advisory and other commercial dealings in the ordinary course of business with us or our affiliates for which they have received and may continue to receive customary fees and commissions.
Determination of Offering Price
The actual offering price of the securities we are offering was negotiated between us, the placement agent and prospective investors, based on the trading of our shares of common stock prior to the offering, among other things, and may be at a discount to the current market price. The securities offered hereby will be sold at a fixed price until the completion of the offering.
S-19
Lock-up Agreement
We have agreed with the investors in this offering, for a period of 60 days following the date of closing of the offering to be subject to a lock-up period, subject to certain customary exceptions. This means that, during the applicable lock-up period, we may not issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of common stock or their equivalents, subject to certain exceptions. In addition, we have agreed to not issue any securities that are subject to a price reset based on the trading prices of our common stock or upon a specified or contingent event in the future or enter into any agreement to issue securities at a future determined price for a period of one year following the closing date of this offering, subject to an exception.
Tail
We have also agreed to pay the placement agent a tail fee equal to the cash and warrant compensation in this offering, if any investor, who was contacted or introduced to us by the placement agent during the term of its engagement, provides us with capital in any public or private offering or other financing or capital raising transaction during the 9-month period following expiration or termination of our engagement of the placement agent, subject to certain exceptions.
Regulation M
The placement agent may be deemed to be an underwriter within the meaning of Section 2(a)(11) of the Securities Act, and any commissions received by the placement agent and any profit realized on the resale of the securities sold by the placement agent while acting as principal might be deemed to be underwriting discounts or commissions under the Securities Act. As an underwriter, the placement agent would be required to comply with the requirements of the Securities Act and the Exchange Act, including, without limitation, Rule 415(a)(4) under the Securities Act and Rule 10b-5 and Regulation M under the Exchange Act. These rules and regulations may limit the timing of purchases and sales of securities by the placement agent acting as principal. Under these rules and regulations, the placement agent (i) may not engage in any stabilization activity in connection with our securities; and (ii) may not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than as permitted under the Exchange Act, until it has completed its participation in the distribution.
Indemnification
We have agreed to indemnify the placement agent and specified other persons against certain liabilities, including liabilities under the Securities Act, relating to or arising out of the placement agents activities under the placement agency agreement and to contribute to payments that the placement agent may be required to make in respect of such liabilities.
Listing
Our shares of common stock are listed on The Nasdaq Global Select Market under the symbol AMRS.
S-20
The validity of the securities offered hereby and certain legal matters in connection with this offering will be passed upon by Fenwick & West LLP, Seattle, Washington. Ellenoff Grossman & Schole LLP, New York, New York will act as counsel for the placement agent in connection with this offering.
The consolidated financial statements of Amyris, Inc. as of December 31, 2020 and 2019 and for the years then ended, incorporated in this prospectus by reference to the Annual Report on Form 10-K for the year ended December 31, 2020, have been so incorporated in reliance on the report (which contains an emphasis paragraph that states that the Company has suffered recurring losses from operations, has an accumulated deficit of $2.1 billion and current debt service requirements that raise substantial doubt about its ability to continue as a going concern) of Macias Gini & OConnell LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.
WHERE YOU CAN FIND MORE INFORMATION
We are subject to the filing requirements of the Securities Exchange Act of 1934 (the Exchange Act). Therefore, we file periodic reports, proxy statements and other information with the Commission. The Commission maintains a website (www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically.
We make our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all amendments to such reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act available free of charge through a link on the Investors section of our website located at www.amyris.com (under Financial InformationSEC Filings) as soon as reasonably practicable after they are filed with or furnished to the Commission. The information contained in or accessible through our website or contained on other websites is not a part of, and is not incorporated into, this prospectus.
S-21
INCORPORATION OF CERTAIN INFORMATION BY REFERENCE
The Commission allows us to incorporate by reference into this prospectus supplement the information we file with it, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus supplement, and information in documents that we subsequently file with the Commission will automatically update and supersede information in this prospectus supplement. We incorporate by reference into this prospectus supplement the documents listed below and any future filings made by us with the Commission under Section 13(a), 13(c), 14 or 15(d) of the Exchange Act (other than those documents or the portions of those documents furnished and not filed in accordance with Commission rules) prior to the termination of this offering, including all filings made after the date of the initial registration statement and prior to the effectiveness of the registration statement. We hereby incorporate by reference the following documents (other than the portions of those documents furnished and not filed in accordance with Commission rules):
| Our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the Commission on March 9, 2022 (including the information incorporated therein from our Definitive Proxy Statement on Schedule 14A filed with the Commission on April 11, 2022); |
| Our Quarterly Report on Form 10-Q for quarters ending March 31, 2022, June 30, 2022, and September 30, 2022, filed with the Commission May 10, 2022, Aug 9, 2022, and November 8, 2022, respectively; |
| Our Current Report on Form 8-K filed with the Commission on January 26, 2022, March 23, 2022, April 22, 2022, May 31, 2022, June 10, 2022, June 15, 2022, July 1, 2022, September 13, 2022, September 14, 2022, October 11, 2022, November 23, 2022, December 16, 2022; and December 21, 2022; |
| The description of our common stock contained in our registration statement on Form 8-A filed with the Commission on September 24, 2010, including any amendment or report filed for the purpose of updating such description. |
We will provide to each person, including any beneficial holder, to whom a prospectus supplement is delivered, at no cost to the requestor, upon written or oral request, a copy of any or all information that has been incorporated by reference in this prospectus supplement but not delivered with this prospectus supplement, including any exhibits that are specifically incorporated by reference in that information. You may request a copy of these filings by sending an e-mail request to Amyris Investor Relations at investor@amyris.com, calling (510) 740-7481, or writing to Amyris Investor Relations at 5885 Hollis Street, Suite 100, Emeryville, California 94608.
Copies of these filings are also available free of charge through a link on the Investors section of our website located at www.amyris.com (under Financial InformationSEC Filings) as soon as reasonably practicable after they are filed with or furnished to the Commission. The information contained in or accessible through our website or contained on other websites is not a part of, and is not incorporated into, this prospectus supplement.
S-22
PROSPECTUS
AMYRIS, INC.
Common Stock
Preferred Stock
Warrants
Debt Securities
Units
The securities covered by this prospectus may include shares of our common stock; shares of preferred stock; warrants to purchase shares of our common stock, preferred stock and/or debt securities; debt securities consisting of debentures, notes or other evidences of indebtedness; or units consisting of any combination of such securities. We or any selling stockholder may offer an indeterminate number of shares of securities from time to time in one or more series or issuances directly to our stockholders or purchasers, or through agents, underwriters or dealers as designated from time to time.
This prospectus provides a general description of the securities we may offer. Each time we sell securities, we will provide specific terms of the securities offered in a supplement to this prospectus. Such a prospectus supplement or any related free writing prospectus may also add, update or change information contained in this prospectus. We or any selling stockholder will sell these securities directly to our stockholders or to purchasers, or through agents on our behalf or through underwriters or dealers as designated from time to time. If any agents or underwriters are involved in the sale of any of these securities, the applicable prospectus supplement will provide the names of the agents or underwriters and any applicable fees, commissions or discounts payable to such agents or underwriters. Each prospectus supplement will provide the amount, price, terms and plan of distribution relating to the securities to be sold pursuant to such prospectus supplement. For additional information on the methods of sale, you should refer to the section entitled Plan of Distribution in this prospectus.
Our common stock is traded on the Nasdaq Global Select Market under the symbol AMRS. On April 6, 2021, the closing price of our common stock was $18.23. None of the other securities we or any selling stockholder may offer are currently traded on any securities exchange.
Investing in our securities involves risks. See Risk Factors commencing on page 3. You should carefully read this prospectus, the documents incorporated herein, and the applicable prospectus supplement before making any investment decision.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.
The date of this prospectus is April 7, 2021
i | ||
1 | ||
3 | ||
4 | ||
5 | ||
6 | ||
10 | ||
11 | ||
19 | ||
20 | ||
22 | ||
22 | ||
22 | ||
23 |
This prospectus is part of an automatic shelf registration statement that we filed with the Securities and Exchange Commission (the Commission), as a well-known seasoned issuer as defined in Rule 405 under the Securities Act of 1933, as amended (the Securities Act). Under this shelf registration process, from time to time, we and/or any selling stockholders may offer to sell any combination of the securities described in this prospectus in one or more offerings. This prospectus provides you with a general description of the securities we and/or selling stockholders may offer. Each time we and/or selling stockholders sell securities under this shelf registration process, we will provide a prospectus supplement that will contain specific information about the terms of such offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement or any free writing prospectus may also add, update or change information contained in this prospectus. If there is any inconsistency between the information contained in this prospectus and any applicable prospectus supplement or free writing prospectus, you should rely on the information in the applicable prospectus supplement or any free writing prospectus; provided that, if any statement in one of these documents is inconsistent with a statement in another document having a later datefor example, a document incorporated by reference in this prospectus or any prospectus supplement or any free writing prospectusthe statement in the document having the later date modifies or supersedes the earlier statement. You should read both this prospectus and any applicable prospectus supplement or free writing prospectus, together with additional information described under Where You Can Find More Information and Incorporation of Certain Information by Reference below.
Neither we nor any selling stockholder have authorized any dealer, agent, underwriter or other person to give any information or to make any representation other than those contained or incorporated by reference in this prospectus and any accompanying prospectus supplement and any free writing prospectus. We and any agent, underwriter or dealer take no responsibility for, and can provide no assurance as to the reliability of any information others may give you. This prospectus and the accompanying prospectus supplement or free writing prospectus, if any, do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus and any accompanying prospectus supplement or any free writing prospectus constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. You should not assume that the information contained in this prospectus and any accompanying prospectus supplement and any free writing prospectus, if any, is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus and any accompanying prospectus supplement and any free writing prospectus is delivered or securities are sold on a later date.
THIS PROSPECTUS MAY NOT BE USED TO OFFER AND SELL SECURITIES UNLESS IT IS ACCOMPANIED BY AN ADDITIONAL PROSPECTUS OR A PROSPECTUS SUPPLEMENT.
Unless the context otherwise requires, AMRS, Amyris, the Company, we, us, our and similar names refer to Amyris, Inc.
i
This summary highlights information contained in other parts of this prospectus or incorporated by reference in this prospectus from our Annual Report on Form 10-K for the year ended December 31, 2020, and our other filings with the SEC listed below under the heading Incorporation by Reference. This summary does not contain all the information that you should consider before investing in our securities. You should carefully read this entire prospectus, any applicable prospectus supplement or free writing prospectus and the information incorporated by reference in this prospectus and any applicable prospectus supplement carefully, including Risk Factors and the financial statements and related notes and other information incorporated by reference, before making an investment decision.
About Amyris, Inc.
As a leading synthetic biotechnology company active in the Clean Health and Beauty markets through our consumer brands and a top supplier of sustainable and natural ingredients, we apply our proprietary Lab-to-Market biotechnology platform to engineer, manufacture and market high performance, natural and sustainably sourced products. We do so with the use of computational tools, strain construction tools, screening and analytics tools, and advanced lab automation and data integration. Our biotechnology platform enables us to rapidly engineer microbes and use them as catalysts to metabolize renewable, plant-sourced sugars into high-value ingredients that we manufacture at industrial scale. Through the combination of our biotechnology platform and our industrial fermentation process, we have successfully developed, produced and commercialized thirteen distinct molecules used in formulations by thousands of leading global brands.
We believe that synthetic biology represents a third industrial revolution, bringing together biology and engineering to generate new, more sustainable materials to meet the growing global demand for bio-based replacements of petroleum-based and traditional animal- or plant-derived ingredients. We continue to generate demand for our current portfolio of products through an extensive go-to-market network provided by our partners that are the leading companies in our target markets. Via our partnership model, our partners invest in the development of molecules to take it from the lab to commercial scale and use their extensive marketing and sales capability to sell our ingredients and formulations to their customers. We capture long-term revenue both through the production and sale of the molecule to our partners and through royalty revenues from our partners product sales to their customers. We have also successfully formulated our unique, natural and sustainably-sourced ingredients into wholly-owned consumer brands, including Biossance® our clean beauty skincare brand, Pipette®, our baby and mother care brand, and PurecaneTM our alternative sweetener brand. We are marketing our brands directly to consumers via our ecommerce platforms, and both in brick and mortar and online via various retail partners.
Corporate Information
We were originally incorporated in California in 2003 under the name Amyris Biotechnologies, Inc. and then reincorporated in Delaware in 2010 and changed our name to Amyris, Inc. Our principal executive offices are located at 5885 Hollis Street, Suite 100, Emeryville, California 94608, and our telephone number is (510) 450-0761. Our common stock is listed on The Nasdaq Global Select Market under the symbol AMRS. Our website address is www.amyris.com. The information contained in or accessible through our website or contained on other websites is not a part of, and not incorporated into, this prospectus.
Amyris, the Amyris logo, Biossance, Pipette, Purecane and No Compromise are trademarks or registered trademarks of Amyris, Inc. or its subsidiaries. This report also contains trademarks and trade names of other businesses that are the property of their respective holders. Solely for convenience, the trademarks and tradenames referred to in this prospectus appear without the ® and symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the applicable licensor to these trademarks and tradenames.
1
THE SECURITIES WE MAY OFFER
With this prospectus, we and/or any selling stockholder may offer shares of our common stock; shares of preferred stock; warrants to purchase shares of our common stock, preferred stock and/or debt securities; debt securities consisting of debentures, notes or other evidences of indebtedness; or units consisting of any combination of such securities, at prices and on terms to be determined at the time of any offering. Each time we and/or any selling stockholders offer securities with this prospectus, we will provide offerees with a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities. The following is a summary of the securities we may offer with this prospectus.
Common Stock
We and/or any selling stockholder may offer shares of our common stock, par value $0.0001 per share.
Preferred Stock
We may offer shares of our preferred stock, par value $0.0001 per share, in one or more series. Our Board of Directors will determine the dividend, voting, conversion and other rights of the series of preferred stock being offered.
Warrants
We may offer warrants for the purchase of debt securities, shares of preferred stock or shares of common stock. Our Board of Directors will determine the terms of the warrants being offered.
Debt Securities
We may offer debt securities, which may be secured or unsecured, senior or subordinated and/or convertible into shares of our common stock or preferred stock. Our Board of Directors will determine the terms of the series of debt securities being offered.
We may issue any debt securities offered with this prospectus under an indenture or indentures between us and a trustee. In this prospectus, we have summarized general features of the debt securities from the indenture. We encourage you to read the indenture, which is an exhibit to the registration statement of which this prospectus is a part.
Units
We may offer units consisting of some or all of the securities described above, in any combination, including common stock, preferred stock, warrants and/or debt securities. The terms of these units will be set forth in a prospectus supplement. The description of the terms of these units in the related prospectus supplement will not be complete. You should refer to the applicable form of unit and unit agreement for complete information with respect to these units.
2
Investing in our securities involves a high degree of risk. The prospectus supplement applicable to each offering of securities hereunder will contain a discussion of the risks applicable to an investment in such securities. Prior to making a decision about investing in our securities, you should carefully read and consider the specific factors discussed under the heading Risk Factors in the applicable prospectus supplement, together with all of the other information contained or incorporated by reference in the prospectus supplement or appearing or incorporated by reference in this prospectus. You should also consider the risks, uncertainties and assumptions discussed under the heading Risk Factors in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2020 and in Part II, Item 1A of any subsequently filed Quarterly Reports on Form 10-Q filed with the Commission, which are incorporated herein by reference, and may be amended, supplemented, or superseded from time to time by other reports we file with the Commission in the future.
Additional risks and uncertainties beyond those set forth in our reports filed with the Commission and not presently known to us or that we currently deem immaterial may also affect our operations. Any risks and uncertainties, whether set forth in our reports filed with the Commission or otherwise, could cause our business, financial condition, results of operations and future prospects to be materially and adversely harmed. The trading price of our securities could decline due to any of these risks and uncertainties, and, as a result, you may lose all or part of your investment.
3
This prospectus, any prospectus supplement and the other documents we have filed with the Commission that are incorporated herein by reference contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties, including those discussed under the heading Risk Factors above, include our liquidity and ability to fund operating and capital expenses, potential delays or failures in development, production and commercialization of products, and our reliance on third parties.
All statements other than statements of historical fact are statements that could be deemed to be forward-looking statements, including any projections of financing needs, revenue, expenses, earnings or losses from operations, or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning product research, development and commercialization plans and timelines; any statements regarding expected production capacities, volumes and costs; any statements regarding anticipated benefits of our products and expectations for commercial relationships; any statements regarding the impact of the COVID-19 pandemic and related health measures on our business, financial condition and liquidity; any other statements of expectation or belief; and any statements of assumptions underlying any of the foregoing. The words believe, anticipate, expect, estimate, intend, plan, project, will be, will continue, will result, seek, could, may, might, or any variations of such words or other words with similar meanings generally identify forward-looking statements.
Given these uncertainties, you should not place undue reliance on these forward-looking statements. You should read this prospectus, any supplements to this prospectus and the documents that we incorporate by reference in this prospectus with the understanding that our actual future results may be materially different from what we expect.
The forward-looking statements in this prospectus and in any prospectus supplement or other document we have filed with the Commission and incorporated herein represent our views as of the date thereof. We anticipate that subsequent events and developments will cause our views to change. All subsequent written or oral forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. However, while we may elect to update these forward-looking statements at some point in the future or to conform these statements to actual results or revised expectations, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this prospectus or such prospectus supplement or other document.
4
We will have broad discretion in the way that we use the net proceeds of any offering under this prospectus. Except as otherwise provided in the applicable prospectus supplement, we intend to use the net proceeds from the sale of the securities covered by this prospectus for general corporate purposes, which may include working capital, capital expenditures, research and development expenditures, commercial expenditures, repayment of indebtedness, acquisitions of new technologies or businesses, and investments. The amounts that we actually spend for the purposes described above may vary significantly and will depend, in part, on the timing and amount of our future revenues, our future expenses and any potential acquisitions that we may propose. Additional information on the use of net proceeds from the sale of securities covered by this prospectus, including any specific plans for such proceeds, may be set forth in any prospectus supplement relating to the specific offering. Unless otherwise set forth in a prospectus supplement, we will not receive any proceeds from the sale of securities by any selling stockholder.
5
The following is a description of our capital stock we and/or any selling stockholder may offer, as well as certain provisions of our certificate of incorporation, bylaws and Delaware law. This is only a summary and is qualified in its entirety by reference to the description of our common stock included in our certificate of incorporation and our bylaws which have been filed as exhibits to the registration statement of which this prospectus is a part, and by the relevant provisions of the Delaware General Corporations Law, or the DGCL. See Where You Can Find Additional Information.
Common Stock
As of April 1, 2021, our authorized capital stock included 350,000,000 shares of common stock, par value $0.0001 per share, of which there were 273,266,917 shares outstanding (as reflected in the records of our stock transfer agent). A description of the material terms and provisions of our restated certificate of incorporation, as amended, and restated bylaws affecting the rights of holders of our common stock is set forth below. The description is intended as a summary only, and is qualified in its entirety by reference to our restated certificate of incorporation, as amended, and our restated bylaws that are filed as exhibits to the registration statement of which this prospectus forms a part.
As of April 1, 2021, we had approximately 84 holders of record of our common stock. The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees.
Dividend Rights
Subject to preferences that may apply to shares of preferred stock outstanding from time to time, the holders of outstanding shares of our common stock are entitled to receive dividends out of funds legally available if our Board of Directors, in its discretion, determines to issue dividends, and only then at the times and in the amounts that our Board of Directors may determine.
Voting Rights
Each holder of our common stock is entitled to one vote for each share of common stock held on all matters submitted to a vote of stockholders. Our restated certificate of incorporation, as amended, eliminates the right of stockholders to cumulate votes for the election of directors and establishes a classified Board of Directors, divided into three classes with staggered three-year terms. Only one class of directors is elected at each annual meeting of our stockholders, with the other classes continuing in office for the remainder of their respective three-year terms.
No Preemptive or Similar Rights
Our common stock is not entitled to preemptive rights and is not subject to conversion, redemption or sinking fund provisions.
Right to Receive Liquidation Distributions
Upon our dissolution, liquidation or winding-up, the assets legally available for distribution to our stockholders are distributable ratably among the holders of our common stock, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights and payment of liquidation preferences, if any, on any outstanding shares of preferred stock.
6
Registration Rights
Certain of our stockholders, including certain entities affiliated with our directors and/or holders of five percent or more of our outstanding common stock, including DSM, Foris, and Vivo, hold registration rights pursuant to the following:
| Letter agreement, dated July 29, 2015, by and among us and certain investors |
| Securities Purchase Agreement, dated May 8, 2017, by and among us and certain investors |
| Securities Purchase Agreement, dated August 2, 2017, by and between us and DSM International B.V. |
| Stockholder Agreement, dated August 3, 2017, by and between us and affiliates of Vivo Capital LLC |
| Amended and Restated Stockholder Agreement, dated August 7, 2017, by and between us and DSM International B.V. |
| Securities Purchase Agreements, dated January 31, 2020, by and between us and the investor named therein, including Foris |
| Security Purchase Agreements, dated June 1, 2020 and June 4, 2020, by and between us and the investors named therein, including affiliates of Foris, Vivo, and FMR, LLC |
| Exchange and Settlement Agreement, dated March 1, 2021, by and between us and Schottenfeld Opportunities Fund II, L.P., Phase Five Partners, LP, and Koyote Trading, LLC |
Transfer Agent and Registrar
The transfer agent and registrar for our common stock is EQ Shareowner Services (formerly Wells Fargo Shareowner Services).
Stock Exchange Listing
Our common stock is listed on the Nasdaq Global Select Market under the symbol AMRS.
Anti-Takeover Provisions
See Anti-Takeover Provisions below for a description of provisions of the Companys certificate of incorporation and bylaws and Delaware law which may have the effect of delaying, deferring or preventing changes in the Companys control.
7
PREFERRED STOCK
As of April 1, 2021, our authorized capital stock included 5,000,000 shares of preferred stock, par value $0.0001 per share, of which 22,140 shares have been designated as Series A 17.38% Convertible Preferred Stock, 105,204 shares have been designated as Series B 17.38% Convertible Preferred Stock, 20,921 shares have been designated as Series C Convertible Preferred Stock, 15,000 shares have been designated as Series D Convertible Preferred Stock, and 102,156.21 shares have been designated as Series E Convertible Preferred Stock, and of which there were no shares of Series A 17.38% Convertible Preferred Stock, no shares of Series B 17.38% Convertible Preferred Stock, no shares of Series C Convertible Preferred Stock, 8,279.99 shares of Series D Convertible Preferred Stock, and no shares of Series E Convertible Preferred Stock issued and outstanding. We are authorized, subject to limitations prescribed by Delaware law, to issue preferred stock in one or more series, to establish from time to time the number of shares to be included in each series and to fix the designation, powers, preferences and rights of each series and any of its qualifications, limitations or restrictions. Our Board of Directors can also increase or decrease the number of authorized shares of any series of preferred stock, but not above the total number of authorized shares of preferred stock nor below the number of shares of that series then outstanding, without any further vote or action by our stockholders. Our Board of Directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our common stock.
The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control of our company and may adversely affect the market price of our common stock and the voting and other rights of the holders of our common stock.
If we offer a specific series of preferred stock under this prospectus, we will describe the terms of the preferred stock in the prospectus supplement for such offering and will file a copy of the certificate of designation establishing the terms of the series of preferred stock with the Commission. To the extent required and applicable, this description will include:
| the number of shares offered, the liquidation preference per share and the purchase price; |
| the dividend rate(s), period(s) and/or payment date(s), or method(s) of calculation for such dividends; |
| whether dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate; |
| the provisions for a sinking fund, if any; |
| the provisions for redemption, if applicable; |
| any listing of the preferred stock on any securities exchange or market; |
| whether the preferred stock will be convertible into our common stock, and, if applicable, the conversion price (or how it will be calculated) and conversion period; |
| whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange price (or how it will be calculated) and exchange period; |
| voting rights, if any, of the preferred stock; |
| a discussion of any material U.S. federal income tax considerations applicable to the preferred stock; |
| the relative ranking and preferences of the preferred stock as to dividend rights and rights upon liquidation, dissolution or winding up of the affairs of our company; and |
| any material limitations on the issuance of any series of preferred stock ranking senior to or on a parity with the series of preferred stock as to dividend rights and rights upon liquidation, dissolution or winding up of our company. |
8
The preferred stock offered under this prospectus, when issued, will not have any preemptive or similar rights.
Transfer Agent and Registrar
The transfer agent and registrar for any series of preferred stock will be set forth in the applicable prospectus supplement.
9
As of April 1, 2021, we had warrants outstanding to purchase 19,589,801 shares of our common stock. We may issue warrants to purchase shares of our common stock, preferred stock and/or debt securities in one or more series together with other securities or separately, as described in each applicable prospectus supplement. Particular terms of the warrants will be described in the applicable warrant agreements and the applicable prospectus supplement for the warrants.
The applicable prospectus supplement will contain, where applicable, the following terms of and other information relating to the warrants:
| the specific designation and aggregate number of, and the price at which we will issue, the warrants; |
| the currency or currency units in which the offering price, if any, and the exercise price are payable; |
| the designation, amount and terms of the securities purchasable upon exercise of the warrants; |
| the exercise price for shares of our common stock and the number of shares of common stock to be received upon exercise of the warrants; |
| the exercise price for shares of our preferred stock, the number of shares of preferred stock to be received upon exercise of the warrants, and a description of that series of our preferred stock; |
| the exercise price for our debt securities, the amount of our debt securities to be received upon exercise of the warrants, and a description of that series of debt securities; |
| the date on which the right to exercise the warrants will begin and the date on which that right will expire or, if the warrants may not be continuously exercised throughout that period, the specific date or dates on which the warrants may be exercised; |
| whether the warrants will be issued in fully registered form or bearer form, in definitive or global form or in any combination of these forms, although, in any case, the form of a warrant included in a unit will correspond to the form of the unit and of any security included in that unit; |
| a discussion of any material U.S. federal income tax considerations applicable to the warrants; |
| the identity of the warrant agent for the warrants and of any other depositaries, execution or paying agents, transfer agents, registrars or other agents for the warrants; |
| any listing of the warrants or any securities purchasable upon exercise of the warrants on any securities exchange; |
| the date from and after which the warrants and the common stock, preferred stock and/or debt securities issuable upon exercise thereof will be separately transferable; |
| the minimum or maximum amount of the warrants that may be exercised at any one time; |
| any information with respect to book-entry procedures; |
| any anti-dilution provisions of the warrants; |
| any redemption or call provisions; |
| whether the warrants are to be sold separately or with other securities as parts of units; and |
| any additional terms of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the warrants. |
Transfer Agent and Registrar
The transfer agent and registrar for any warrants will be set forth in the applicable prospectus supplement.
10
DESCRIPTION OF DEBT SECURITIES
We will issue the debt securities offered under this prospectus and any accompanying prospectus supplement under an indenture to be entered into between us and the trustee identified in the applicable prospectus supplement. The terms of the debt securities will include those stated in the indenture and those made part of the indenture by reference to the Trust Indenture Act of 1939, as in effect on the date of the indenture. We have filed a copy of the form of indenture as an exhibit to the registration statement of which this prospectus forms a part. The indenture will be subject to and governed by the terms of the Trust Indenture Act of 1939. Unless otherwise specified in the applicable prospectus supplement, the debt securities will represent our direct, unsecured obligations and will rank equally with all of our other unsecured indebtedness.
The following statements relating to the debt securities and the indenture are summaries, qualified in their entirety by reference to the detailed provisions of the debt securities we issue and the indenture we enter into with the trustee.
General
We may issue the debt securities in one or more series with the same or various maturities, at par, at a premium, or at a discount. We will describe the particular terms of each series of debt securities in a prospectus supplement relating to that series.
The prospectus supplement will set forth, to the extent required and applicable, the following terms of the debt securities in respect of which the prospectus supplement is delivered:
| the title of the debt securities; |
| the aggregate principal amount, and, if a series, the total amount authorized and the total amount outstanding; |
| the issue price or prices, expressed as a percentage of the aggregate principal amount of the debt securities; |
| any limit on the aggregate principal amount; |
| the date or dates on which principal is payable; |
| the interest rate or rates (which may be fixed or variable) or, if applicable, the method used to determine such rate or rates; |
| the date or dates from which interest, if any, will be payable and any regular record date for the interest payable; |
| the place or places where principal and, if applicable, premium and interest, is payable; |
| the terms and conditions upon which we may, or the holders may require us to, redeem or repurchase the debt securities; |
| the denominations in which such debt securities may be issuable, if other than denominations of $1,000 or any integral multiple of that number; |
| whether the debt securities are to be issuable in the form of certificated securities (as described below) or global securities (as described below); |
| the portion of principal amount that will be payable upon declaration of acceleration of the maturity date if other than the principal amount of the debt securities; |
| the currency of denomination; |
| the designation of the currency, currencies or currency units in which payment of principal and, if applicable, premium and interest, will be made; |
11
| if payments of principal and, if applicable, premium or interest on the debt securities are to be made in one or more currencies or currency units other than the currency of denomination, the manner in which the exchange rate with respect to such payments will be determined; |
| if amounts of principal and, if applicable, premium and interest may be determined by reference to an index based on a currency or currencies or by reference to a commodity, commodity index, stock exchange index or financial index, then the manner in which such amounts will be determined; |
| the provisions, if any, relating to any collateral provided as security for the payment of such debt securities; |
| any addition to or change in the covenants and/or the acceleration provisions described in this prospectus or in the indenture; |
| any events of default, if not otherwise described below under Events of Default; |
| the terms and conditions, if any, for the conversion of such debt securities into, or the exchange of such debt securities for, shares of our common stock or preferred stock; |
| any depositaries, interest rate calculation agents, exchange rate calculation agents or other agents for the debt securities; and |
| the terms and conditions, if any, upon which the debt securities shall be subordinated in right of payment to our other indebtedness. |
We may issue discounted debt securities that provide for an amount less than the stated principal amount to be due and payable upon acceleration of the maturity of such debt securities in accordance with the terms of the indenture. We may also issue debt securities in bearer form, with or without coupons. If we issue discounted debt securities or debt securities in bearer form, we will describe material U.S. federal income tax considerations and other material special considerations which apply to these debt securities in the applicable prospectus supplement.
We may issue debt securities denominated in or payable in a foreign currency or currencies or a foreign currency unit or units. If we do, we will describe the restrictions, elections, and general tax considerations relating to the debt securities and the foreign currency or currencies or foreign currency unit or units in the applicable prospectus supplement.
Debt securities offered under this prospectus and any prospectus supplement will be subordinated in right of payment to certain of our outstanding senior indebtedness, as further described in the applicable prospectus supplement. In addition, we will seek the consent of the holders of any such senior indebtedness prior to issuing any debt securities under this prospectus to the extent required by the agreements evidencing such senior indebtedness.
Exchange and/or Conversion Rights
We may issue debt securities that can be exchanged for or converted into shares of our common stock or preferred stock. If we do, we will describe the terms of exchange or conversion in the prospectus supplement relating to these debt securities.
Transfer and Exchange
We may issue debt securities that will be represented by either:
| book-entry securities, which means that there will be one or more global securities registered in the name of a depositary or a nominee of a depositary; or |
12
| certificated securities, which means that they will be represented by a certificate issued in definitive registered form. |
We will specify in the prospectus supplement applicable to a particular offering whether the debt securities offered will be book-entry or certificated securities.
Registrar and Paying Agent
The debt securities may be presented for registration of transfer or for exchange at the corporate trust office of the security registrar or at any other office or agency that we maintain for those purposes. In addition, the debt securities may be presented for payment of principal, interest and any premium at the office of the paying agent or at any office or agency that we maintain for those purposes.
Global Securities
If we decide to issue debt securities in the form of one or more global securities, then we will register the global securities in the name of the depositary for the global securities or the nominee of the depositary, and the global securities will be delivered by the trustee to the depositary for credit to the accounts of the holders of beneficial interests in the debt securities.
The prospectus supplement will describe the specific terms of the depositary arrangement for debt securities that are issued in global form. None of us, the trustee, any payment agent or the security registrar will have any responsibility or liability for any aspect of the records relating to or payments made on account of beneficial ownership interests in a global debt security or for maintaining, supervising or reviewing any records relating to these beneficial ownership interests.
No Protection in the Event of Change of Control
The indenture does not have any covenants or other provisions providing for a put or increased interest or otherwise that would afford holders of our debt securities additional protection in the event of a recapitalization transaction, a change of control, or a highly leveraged transaction. If we offer any covenants or provisions of this type with respect to any debt securities covered by this prospectus, we will describe them in the applicable prospectus supplement.
Covenants
Unless otherwise indicated in this prospectus or the applicable prospectus supplement, our debt securities will not have the benefit of any covenants that limit or restrict our business or operations, the pledging of our assets or the incurrence by us of indebtedness. We will describe in the applicable prospectus supplement any material covenants in respect of a series of debt securities.
Consolidation, Merger and Sale of Assets
The form of indenture provides that we will not consolidate with or merge into any other person or convey, transfer, sell or lease our properties and assets substantially as an entirety to any person, unless:
| the person formed by the consolidation or into or with which we are merged or the person to which our properties and assets are conveyed, transferred, sold or leased, is a corporation organized and existing under the laws of the U.S., any state or the District of Columbia or a corporation or comparable legal entity organized under the laws of a foreign jurisdiction and, if we are not the surviving person, the surviving person has expressly assumed all of our obligations, including the payment of the principal of, and premium, if any, and interest on the debt securities and the performance of the other covenants under the indenture; and |
13
| immediately before and immediately after giving effect to the transaction, no event of default, and no event which, after notice or lapse of time or both, would become an event of default, has occurred and is continuing under the indenture. |
Events of Default
Unless otherwise specified in the applicable prospectus supplement, the following events will be events of default under the indenture with respect to debt securities of any series:
| we fail to pay any principal or premium, if any, within 30 days after it becomes due; |
| we fail to pay any interest within 60 days after it becomes due; |
| we fail to observe or perform any other covenant in the debt securities or the indenture for 90 days after written notice specifying the failure from the trustee or the holders of not less than 25% in aggregate principal amount of the outstanding debt securities of that series; and |
| certain events involving bankruptcy, insolvency or reorganization of us or any of our significant subsidiaries. |
The trustee may withhold notice to the holders of the debt securities of any series of any default, except in payment of principal of, or premium, if any, or interest on the debt securities of a series, if the trustee considers it to be in the best interest of the holders of the debt securities of that series to do so.
If an event of default (other than an event of default resulting from certain events of bankruptcy, insolvency or reorganization) occurs, and is continuing, then the trustee or the holders of not less than 25% in aggregate principal amount of the outstanding debt securities of any series may accelerate the maturity of the debt securities. If this happens, the entire principal amount, plus the premium, if any, of all the outstanding debt securities of the affected series plus accrued interest to the date of acceleration will become immediately due and payable. At any time after the acceleration, but before a judgment or decree based on such acceleration is obtained by the trustee, the holders of a majority in aggregate principal amount of outstanding debt securities of such series may rescind and annul such acceleration if:
| all events of default (other than nonpayment of accelerated principal, premium or interest) have been cured or waived; |
| all lawful interest on overdue interest and overdue principal has been paid; and |
| the rescission would not conflict with any judgment or decree. |
In addition, if the acceleration occurs at any time when we have outstanding indebtedness that is senior to the debt securities, the payment of the principal amount of outstanding debt securities may be subordinated in right of payment to the prior payment of any amounts due under the senior indebtedness, in which case the holders of debt securities will be entitled to payment under the terms prescribed in the instruments evidencing the senior indebtedness and the indenture.
If an event of default resulting from certain events of bankruptcy, insolvency or reorganization occurs, the principal, premium and interest amount with respect to all of the debt securities of any series will become due and payable immediately without any declaration or other act on the part of the trustee or the holders of the debt securities of that series.
The holders of a majority in principal amount of the outstanding debt securities of a series will have the right to waive any existing default or compliance with any provision of the indenture or the debt securities of that series and to direct the time, method and place of conducting any proceeding for any remedy available to the trustee, subject to certain limitations specified in the indenture.
14
No holder of any debt security of a series will have any right to institute any proceeding with respect to the indenture or for any remedy under the indenture, unless:
| the holder gives to the trustee written notice of a continuing event of default; |
| the holders of at least 25% in aggregate principal amount of the outstanding debt securities of the affected series make a written request and offer reasonable indemnity to the trustee to institute a proceeding as trustee; |
| the trustee fails to institute a proceeding within 60 days after such request; and |
| the holders of a majority in aggregate principal amount of the outstanding debt securities of the affected series do not give the trustee a direction inconsistent with such request during such 60-day period. |
These limitations do not, however, apply to a suit instituted for payment on debt securities of any series on or after the due dates expressed in the debt securities.
We will periodically deliver certificates to the trustee regarding our compliance with our obligations under the indenture.
Modification and Waiver
From time to time, we and the trustee may, without the consent of holders of the debt securities of one or more series, amend the indenture or the debt securities of one or more series, or supplement the indenture, for certain specified purposes, including:
| to provide that the surviving entity following a change of control permitted under the indenture will assume all of our obligations under the indenture and debt securities; |
| to provide for certificated debt securities in addition to uncertificated debt securities; |
| to comply with any requirements of the Commission under the Trust Indenture Act of 1939; |
| to provide for the issuance of and establish the form and terms and conditions of debt securities of any series as permitted by the indenture; |
| to cure any ambiguity, defect or inconsistency, or make any other change that does not materially and adversely affect the rights of any holder; and |
| to appoint a successor trustee under the indenture with respect to one or more series. |
From time to time we and the trustee may, with the consent of holders of at least a majority in principal amount of an outstanding series of debt securities, amend or supplement the indenture or the debt securities of such series, or waive compliance in a particular instance by us with any provision of the indenture or the debt securities. We may not, however, without the consent of each holder affected by such action, modify or supplement the indenture or the debt securities or waive compliance with any provision of the indenture or the debt securities in order to:
| reduce the amount of debt securities whose holders must consent to an amendment, supplement, or waiver to the indenture or such debt securities; |
| reduce the rate of or change the time for payment of interest or reduce the amount of or postpone the date for payment of sinking fund or analogous obligations; |
| reduce the principal of or change the stated maturity of the debt securities; |
| make any debt security payable in money other than that stated in the debt security; |
15
| change the amount or time of any payment required or reduce the premium payable upon any redemption, or change the time before which no such redemption may be made; |
| waive a default in the payment of the principal of, or premium, if any, or interest on the debt securities or a redemption payment; |
| waive a redemption payment with respect to any debt securities or change any provision with respect to redemption of debt securities; or |
| take any other action otherwise prohibited by the indenture to be taken without the consent of each holder affected by the action. |
Defeasance of Debt Securities and Certain Covenants in Certain Circumstances
The indenture permits us, at any time, to elect to discharge our obligations with respect to one or more series of debt securities by following certain procedures described in the indenture. These procedures will allow us either:
| to defease and be discharged from any and all of our obligations with respect to any debt securities except for the following obligations (which discharge is referred to as legal defeasance): |
| to register the transfer or exchange of such debt securities; |
| to replace temporary or mutilated, destroyed, lost or stolen debt securities; |
| to compensate and indemnify the trustee; or |
| to maintain an office or agency in respect of the debt securities and to hold monies for payment in trust; or |
| to be released from our obligations with respect to the debt securities under certain covenants contained in the indenture, as well as any additional covenants which may be contained in any applicable supplemental indenture (which release is referred to as covenant defeasance). |
In order to exercise either defeasance option, we must deposit with the trustee or other qualifying trustee, in trust for that purpose:
| money; |
| U.S. Government Obligations (as described below) or Foreign Government Obligations (as described below) that through the scheduled payment of principal and interest in accordance with their terms will provide money; or |
| a combination of money and/or U.S. Government Obligations and/or Foreign Government Obligations sufficient in the written opinion of a nationally-recognized firm of independent accountants to provide money; |
that, in each case specified above, provides a sufficient amount to pay the principal of, and premium, if any, and interest, if any, on the debt securities of the series, on the scheduled due dates or on a selected date of redemption in accordance with the terms of the indenture.
In addition, defeasance may be effected only if, among other things:
| in the case of either legal or covenant defeasance, we deliver to the trustee an opinion of counsel, as specified in the indenture, stating that as a result of the defeasance neither the trust nor the trustee will be required to register as an investment company under the Investment Company Act of 1940; |
| in the case of legal defeasance, we deliver to the trustee an opinion of counsel stating that we have received from, or there has been published by, the Internal Revenue Service a ruling to the effect that, |
16
or there has been a change in any applicable federal income tax law with the effect that (and the opinion shall confirm that), the holders of outstanding debt securities will not recognize income, gain or loss for U.S. federal income tax purposes solely as a result of such legal defeasance and will be subject to U.S. federal income tax on the same amounts, in the same manner, including as a result of prepayment, and at the same times as would have been the case if legal defeasance had not occurred; |
| in the case of covenant defeasance, we deliver to the trustee an opinion of counsel to the effect that the holders of the outstanding debt securities will not recognize income, gain or loss for U.S. federal income tax purposes as a result of covenant defeasance and will be subject to U.S. federal income tax on the same amounts, in the same manner and at the same times as would have been the case if covenant defeasance had not occurred; and |
| certain other conditions described in the indenture are satisfied. |
If we fail to comply with our remaining obligations under the indenture and any applicable supplemental indenture after a covenant defeasance of the indenture and applicable supplemental indenture, and the debt securities are declared due and payable because of the occurrence of any undefeased event of default, the amount of money and/or U.S. Government Obligations and/or Foreign Government Obligations on deposit with the trustee could be insufficient to pay amounts due under the debt securities of the affected series at the time of acceleration. We will, however, remain liable in respect of these payments.
The term U.S. Government Obligations as used in the above discussion means securities that are direct obligations of or non-callable obligations guaranteed by the United States of America for the payment of which obligation or guarantee the full faith and credit of the United States of America is pledged.
The term Foreign Government Obligations as used in the above discussion means, with respect to debt securities of any series that are denominated in a currency other than U.S. dollars, (1) direct obligations of the government that issued or caused to be issued such currency for the payment of which obligations its full faith and credit is pledged or (2) obligations of a person controlled or supervised by or acting as an agent or instrumentality of such government the timely payment of which is unconditionally guaranteed as a full faith and credit obligation by that government, which in either case under clauses (1) or (2), are not callable or redeemable at the option of the issuer.
Regarding the Trustee
We will identify the trustee with respect to any series of debt securities in the prospectus supplement relating to the applicable debt securities. You should note that if the trustee becomes a creditor of ours, the indenture and the Trust Indenture Act of 1939 limit the rights of the trustee to obtain payment of claims in certain cases, or to realize on certain property received in respect of any such claim, as security or otherwise. The trustee and its affiliates may engage in, and will be permitted to continue to engage in, other transactions with us and our affiliates. If, however, the trustee acquires any conflicting interest within the meaning of the Trust Indenture Act of 1939, it must eliminate such conflict or resign.
The holders of a majority in principal amount of the then outstanding debt securities of any series may direct the time, method and place of conducting any proceeding for exercising any remedy available to the trustee. If an event of default occurs and is continuing, the trustee, in the exercise of its rights and powers, must use the degree of care and skill of a prudent person in the conduct of his or her own affairs. Subject to that provision, the trustee will be under no obligation to exercise any of its rights or powers under the indenture at the request of any of the holders of the debt securities, unless such holder(s) have offered to the trustee reasonable indemnity or security.
No Individual Liability of Incorporators, Stockholders, Officers or Directors
The indenture provides that no incorporator and no past, present or future stockholder, officer or director of our company or any successor corporation in those capacities will have any individual liability for any of our obligations, covenants or agreements under the debt securities or such indenture.
17
Governing Law
The indenture and the debt securities will be governed by, and construed in accordance with, the laws of the State of New York.
18
We may issue units consisting of some or all of the securities described above, in any combination, including common stock, preferred stock, warrants and/or debt securities. The terms of these units will be set forth in a prospectus supplement. The description of the terms of these units in the related prospectus supplement will not be complete. You should refer to the applicable form of unit and unit agreement for complete information with respect to these units.
19
The provisions of Delaware law, our restated certificate of incorporation, as amended, and our restated bylaws may have the effect of delaying, deferring or discouraging another person from acquiring control of our company.
Delaware Law
Section 203 of the Delaware General Corporation Law (Section 203) prevents some Delaware corporations from engaging, under some circumstances, in a business combination, which includes a merger or sale of at least 10% of the corporations assets, with any interested stockholder, meaning a stockholder who, together with affiliates and associates, owns or, within three years prior to the determination of interested stockholder status, did own 15% or more of the corporations outstanding voting stock, unless:
| the transaction is approved by the Board of Directors prior to the time that the interested stockholder became an interested stockholder; |
| upon consummation of the transaction which resulted in the stockholders becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced; or |
| at or subsequent to such time that the stockholder became an interested stockholder, the business combination is approved by the Board of Directors and authorized at an annual or special meeting of stockholders by at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder. |
If Section 203 applied to us, these restrictions could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, could discourage attempts to acquire us.
A Delaware corporation may opt out of the restrictions on business combinations contained in Section 203 with an express provision in its original certificate of incorporation or an express provision in its certificate of incorporation or bylaws resulting from a stockholders amendment approved by at least a majority of its outstanding voting shares. We have agreed to opt out of Section 203 through our restated certificate of incorporation, as amended, but our restated certificate of incorporation as amended, contains substantially similar protections to our company and stockholders as those afforded under Section 203.
Restated Certificate of Incorporation and Restated Bylaw Provisions
Our restated certificate of incorporation, as amended, and our restated bylaws include a number of provisions that may have the effect of deterring hostile takeovers or delaying or preventing changes in control of our company or management team, including the following:
| Board of Directors Vacancies. Our restated certificate of incorporation, as amended, and restated bylaws authorize only our Board of Directors to fill vacant directorships. In addition, the number of directors constituting our Board of Directors will be set only by resolution adopted by a majority vote of our entire Board of Directors. These provisions prevent stockholders from increasing the size of our Board of Directors and gaining control of our Board of Directors by filling the resulting vacancies with their own nominees. |
| Classified Board. Our restated certificate of incorporation, as amended, and restated bylaws provide that our Board of Directors is classified into three classes of directors. The existence of a classified board could delay a successful tender offeror from obtaining majority control of our Board of Directors, and the prospect of that delay might deter a potential offeror. Pursuant to Delaware law, the directors of a corporation having a classified board may be removed by the stockholders only for cause. In addition, stockholders will not be permitted to cumulate their votes for the election of directors. |
20
| Stockholder Action; Special Meeting of Stockholders. Our restated certificate of incorporation, as amended, provides that our stockholders may not take action by written consent, but may only take action at annual or special meetings of our stockholders. Our restated bylaws further provide that special meetings of our stockholders may be called only by a majority of our Board of Directors, the chair of our Board of Directors, our chief executive officer or our president. |
| Advance Notice Requirements for Stockholder Proposals and Director Nominations. Our restated bylaws provide for advance notice procedures for stockholders seeking to bring business before our annual meeting of stockholders, or to nominate candidates for election as directors at our annual meeting of stockholders. Our restated bylaws also specify certain requirements regarding the form and content of a stockholders notice. These provisions may preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders. |
| Issuance of Undesignated Preferred Stock. Under our restated certificate of incorporation, as amended, our Board of Directors has the authority, without further action by the stockholders, to issue shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by the Board of Directors. The existence of authorized but unissued shares of preferred stock enables our Board of Directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. |
| Exclusive Forum. Our restated bylaws to provide that, to the fullest extent permitted by law, the Court of Chancery of the State of Delaware will be the exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the DGCL, our certificate of incorporation, or our restated bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. Our restated bylaws further provide that the U.S. federal district courts will, to the fullest extent permitted by law, be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, or a Federal Forum Provision. Our decision to adopt a Federal Forum Provision followed a decision by the Supreme Court of the State of Delaware holding that such provisions are facially valid under Delaware law. While there can be no assurance that federal or state courts will follow the holding of the Delaware Supreme Court or determine that the Federal Forum Provision should be enforced in a particular case, application of the Federal Forum Provision means that suits brought by our stockholders to enforce any duty or liability created by the Securities Act must be brought in federal court and cannot be brought in state court. |
21
The validity of the issuance of the securities offered hereby will be passed upon for us by Fenwick & West LLP, Mountain View, California. Any underwriters or agents will be advised about legal matters relating to any offering by their own counsel.
The consolidated financial statements of Amyris, Inc. as of December 31, 2020 and 2019 and for the years then ended, incorporated in this prospectus by reference to the Annual Report on Form 10-K for the year ended December 31, 2020, have been so incorporated in reliance on the report (which contains an emphasis paragraph that states that the Company has suffered recurring losses from operations, has an accumulated deficit of $2.1 billion and current debt service requirements that raise substantial doubt about its ability to continue as a going concern) of Macias Gini & OConnell LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.
WHERE YOU CAN FIND MORE INFORMATION
We are subject to the filing requirements of the Securities Exchange Act of 1934 (the Exchange Act). Therefore, we file periodic reports, proxy statements and other information with the Commission. The Commission maintains a website (www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically.
We make our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all amendments to such reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act available free of charge through a link on the Investors section of our website located at www.amyris.com (under Financial InformationSEC Filings) as soon as reasonably practicable after they are filed with or furnished to the Commission. The information contained in or accessible through our website or contained on other websites is not a part of, and is not incorporated into, this prospectus.
22
INCORPORATION OF CERTAIN INFORMATION BY REFERENCE
The Commission allows us to incorporate by reference into this prospectus the information we file with it, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus, and information in documents that we subsequently file with the Commission will automatically update and supersede information in this prospectus. We incorporate by reference into this prospectus the documents listed below and any future filings made by us with the Commission under Section 13(a), 13(c), 14 or 15(d) of the Exchange Act (other than those documents or the portions of those documents furnished and not filed in accordance with Commission rules) prior to the termination of this offering, including all filings made after the date of the initial registration statement and prior to the effectiveness of the registration statement. We hereby incorporate by reference the following documents (other than the portions of those documents furnished and not filed in accordance with Commission rules):
| Our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the Commission on March 5, 2021; |
| Our Current Report on Form 8-K filed with the Commission on April 5, 2021; and |
| The description of our common stock contained in our registration statement on Form 8-A filed with the Commission on September 24, 2010, including any amendment or report filed for the purpose of updating such description. |
We will provide to each person, including any beneficial holder, to whom a prospectus is delivered, at no cost to the requestor, upon written or oral request, a copy of any or all information that has been incorporated by reference in this prospectus but not delivered with this prospectus, including any exhibits that are specifically incorporated by reference in that information. You may request a copy of these filings by sending an e-mail request to Amyris Investor Relations at investor@amyris.com, calling (510) 740-7481, or writing to Amyris Investor Relations at 5885 Hollis Street, Suite 100, Emeryville, California 94608.
Copies of these filings are also available free of charge through a link on the Investors section of our website located at www.amyris.com (under Financial InformationSEC Filings) as soon as reasonably practicable after they are filed with or furnished to the Commission. The information contained in or accessible through our website or contained on other websites is not a part of, and is not incorporated into, this prospectus.
23
20,000,000 Shares of Common Stock
Warrants to Purchase up to 15,000,000 Shares of Common Stock
PROSPECTUS SUPPLEMENT
H.C. Wainwright & Co.
December 29, 2022
-_P7YC
M8D%__GZ21&& ?W\%'V2!_H <_+A^=(MYY ]^5XFRRMM^3X@4L3Y^7(:TER]^
M@H6;?)-^OH2Z8.E_#X/T0P!_EH-X':* Y(/?^J-])9<(XDA]')0QR5A])9%Z
MK\Y]2X\>E=9]AHT->TY]UXL\7[1^-XF)0 O=9Y9+XVK5IS3
M''BHX)- !H>EZX1J "#'( >MS$G:\^;3Z^X:N37PFY.*A;4"JSS*8S0(6N
MUZ3.+[FJL*!%'+.H,9-G!LBE1H26 "#'( YA]V<',8T!MW2W/QN8!X'W3,
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MA9ZU#VIU'XILVLMN&\[&Q41O*5_$'+*K/1_'7//EQ]_-731@'5_
M5G7=:.Y_B';V4#%_SW@(-)J 67D'#UB!\GD\U(Q]47Q_P+)] !8-^)H.Z
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M/'6$2I@^(L"$,)6= =6#)X$]L)**!S/X_.#65SXXD.
MT!5HN:_4N]UJ9ZN*INMK^:
#J9-&46V"
M\I&*/U6"99!"*V^!^Y =$>6"'HP9 " ( CR"%O*&^@0F$V9^6<>F#X9T;
M8
DVI?]9JZ@#%B<)?>;#UD
MWI4Q5VIG&I+ 07%HNY"O*&!H%X_*!WQS6840MHY9?ZL.I05<8J=\DIQ>_J.^
M?U]A=J (:VYCYYR95JUF+)F/0-9GR9
(8G*%?^>$8DV!4V9JX.6 ""
M%H " ( 5F*G-))^3 RD>I(B0*>ANI%5-"Z?(Y"D)F>=+Y"9%B:<]HWD
M!6J8<(.I "!@( " ( M29A4UFRH_YCT5T#DC9F+V W?X9H<6-,:]YJ
MGV9&5RALKFDE02IN8FO/)^MNVFW=!KETHV[%LRI=SF1AHG%@FF:LD-1C-FCF
M?DMEKFL0:KIH#6TH5AYJ0&\N0#5K_'$&)QAL$G)>!F-U-7-!L4Y:L6\!H*I=
MLW!*CTU@@W&,?-9C)G+.:6YEK'0-5/MG_G5#/SYINW96)E%I97<*!A=UM7@B
MKW17Y7F!GMU;%GGIH70<%HV9A3+B)I&)=@%>5I3([. " ( CGQXYUBQ@2=Y
M4EP)
H
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MQ6'F25%LJ647-+-N!F?M&]=M@FF; " &WPF\1>$%UTC5Y@L6!D?=IC)V,U
M;4)E?F7F6X1GMVAW2))IMFKD-!=K VT!&V=J36X@ " '+3F@M:6F=9BYY=
M0VEF?$]?]6M<:\QB?FT\6CQDXF\)1W=F^W"\,RMH+7(N&KIGD7+/ " '>#
MF%)6_7$FB>Y:(G)?>JY= W.':GA?MG2=60AB176G1G5D<7:D,F%EA7=V&BME
M.W>V " 'N6EKA4!7KLB'5777M?>4E::GN]:1Y=/GP*6 )?ZGQ618YB*'RD
M,:UC&WSE&;!C1'SN " '\2E611@H2UASQ5 81D>"M8,8/Z:!5;)8."5PQ=
MXX,21-5@)(*Y,1I@](*!&4AAI8*A " ( E%%/:(YSAC]3!HU?=T-63XPK
M9S]96HKR5D)<*XG41"M>;HCF,*E?%(A2&/Q@38A) " ( DX%-N)@:A7M1
M;99$=HA4Q91)9I%7VY)259U:MY"30XQ<^H\M,"Q=>(Y\&+E?.8SM " (
MDO1,=Z&7A.U0-Y\$=?=3DYQ$9@=6JYF95259B)=)0RQ;QI6-+\E<$Y3[&%E>
M9I!V " ( D5AIK%-B@YYK3%
QYZQC#5J7)JCBG!95):2B,%(L))@AQ(XKXW^A6XI^HE'@\FL[:K]FO6<:J:6
ME]2+JJ))E.=ZM)X9DBQIL)GYCX-8S97RC/A(5)'%BE8X@HUQAZ4J!(C1A."L
M1*IBHS>;R:7]GU*+"Z&PFYEZ&IV$F AI(YEFE(585I51D05( I$PC6LX6HSP
MB:\J#8ANA=2KGJGOJUZ;1*6 IJB*CJ$MHAAYG9T G:]HLYCOF517_93FE.5'
MQ9"[D$TX/HR(BX \NFBZ[W@ M*JG"'A'KJZ2
MO'BOJ)M^87E+HHYJ&7H3G&U6&'KQE@1"4GOZCRDO)GTPA['-KW=JQ%ZZ7'>L
MO::F7W?HMI22"'A%KUI]N7C@J"1IB7FOH-95I'J:F3Q!_WNPD2XN_WSOB)7(
M"8?2<06V.H;H